Section 1. XVI Symposium «Current problems of chemistry, biology and technology of natural compounds»

IN SILICO PROFILING OF THE BIOLOGICAL ACTIVITY AND ADVERSE-EFFECT SPECTRUM OF A NOVEL 2-HYDROXYNAPHTHALDEHYDE-DERIVED TOSYLHYDRAZINECARBOXAMIDE

G.Y. To‘raeva 🎤
A.S. Sadikov Institute of Bioorganic Chemistry, Academy of Sciences of the Republic of Uzbekistan, Tashkent, Republic of Uzbekistan
R.S. Esanov
A.S. Sadikov Institute of Bioorganic Chemistry, Academy of Sciences of the Republic of Uzbekistan, Tashkent, Republic of Uzbekistan
M.J. Rakhmatova
S.Y. Yunusov Institute of the Chemistry of Plant Substances, Uzbekistan
B.D. Rakhmonov
National Unversity of Uzbekistan named after Mirzo Ulugbek, Tashkent, Republic of Uzbekistan
👁️ 1 Views
📥 0 Downloads

Abstract

Hydrazone derivatives are an important class of compounds exhibiting diverse biological activities and considerable potential in medicinal chemistry. Early in silico screening enables the identification of promising pharmacological targets before experimental investigations. In this study, the biological activity and adverse-effect spectra of the newly synthesized (E)-2-((2-hydroxynaphthalen-1-yl)methylene)-N-tosylhydrazinecarboxamide were predicted using the PASS Online platform. PASS analysis revealed a broad spectrum of predicted biological activities (Figure 1). The highest probability was observed for glutamyl endopeptidase II inhibition (Pa = 0.766, Pi = 0.015), followed by HMGCS2 expression enhancement (Pa = 0.710), polyprotein protease inhibition (Pa = 0.708), and anti-infective activity (Pa = 0.707). In addition, insulysin (insulin-degrading enzyme, IDE) inhibition was predicted with Pa = 0.694 and Pi = 0.009. Considering the role of IDE in insulin metabolism, this target appears promising for subsequent molecular docking and experimental validation. The predicted adverse-effect profile (Figure 2) was mainly represented by metabolic acidosis (Pa = 0.741, Pi = 0.020) and porphyria (Pa = 0.703, Pi = 0.007), whereas the remaining predicted adverse effects demonstrated considerably lower probabilities. These findings indicate that safety-related endpoints should also be evaluated during further pharmacological investigations.

References

  1. D. A. Filimonov, A. A. Lagunin, T. A. Gloriozova, A. V. Rudik, D. S. Druzhilovskii, P. V. Pogodin, V. V. Poroikov. (2014). Prediction of the Biological Activity Spectra of Organic Compounds Using the Pass Online Web Resource.Chemistry of Heterocyclic Compounds.[Crossref]
  2. Michele Cerasuolo, Maria Chiara Auriemma, Irene Di Meo, Carmen Lenti, Michele Papa, Giuseppe Paolisso, Maria Rosaria Rizzo. (2025). Understanding the Insulin-Degrading Enzyme: A New Look at Alzheimer’s Disease and Aβ Plaque Management.International Journal of Molecular Sciences.[Crossref]
  3. Varshini V. Suresh, Sathish Sivaprakasam, Yangzom D. Bhutia, Puttur D. Prasad, Muthusamy Thangaraju, Vadivel Ganapathy. (2025). Not Just an Alternative Energy Source: Diverse Biological Functions of Ketone Bodies and Relevance of HMGCS2 to Health and Disease.Biomolecules.[Crossref]

Share this Publication

𝕏 Sharein Share✈️ Share💬 Sharef Share

Publication Details

Published Date07/10/2026
ConferenceInternational Conference “Biologically active compounds: From chemistry to medicine”
DOI10.5281/zenodo.23061290
Pages189
CC BY 4.0

This article is licensed under a Creative Commons Attribution 4.0 International License.